



AGENDA

**2018 INTERNATIONAL SYMPOSIUM ON THE FRONTIERS AND PRACTICE
OF INNOVATIVE DRUG DISCOVERY**

October 17, 2018	
15:00-21:00	On-site Registration (1 st Floor, Outside of Lobby)
October 18, 2018 (Grand Ballroom)	
08:00-09:00	On-site Registration (5th Floor)
OPENING CEREMONY	
09:00-9:20	Welcome Speech & Introduction of Speakers
09:20-09:45	Introduction of Chengdu Tianfu International Bio-town
Session1: Analysis of Industrial Trends and Policies, Frontiers in Innovative Drug Discovery & Development Chair: Dr. Emil Fu, SVP of International Integration, Fountain Medical Development	
09:45-10:15	Clinical Trials and IND filing in China and the US Dr. Z. Alex Xu, Chief Scientist, CFDA/CDE
10:15-10:40	Design and molecular assessment approaches for optimal bispecific antibodies Dr. Will Somers, Vice President and Head of BioMedicine Design, Pfizer
10:40-11:10	Conference Photo & Tea Break
11:10-11:35	Synergies Between Innovation and Drug Development at Scripps Dr. Matthew Tremblay, Chief Operating Officer of The Scripps Research Institute & California Institute for Biomedical Research
11:35-12:00	Transforming early innovation into therapeutic solutions through external innovation Dr. Hubert Haag, Director, Tech Platforms Business Dev & Licensing, Global Business Development & Licensing, SANOFI
12:00-13:00	Lunch & Exhibition & Poster Presentation
13:00-13:25	Non-nucleotide Small Molecule STING Agonists for Solid Tumors Dr. Xiaodong Zhang Senior Director of Biology in Discovery Project Unit, HitGen Ltd.
13:25-13:50	Innovative Drug development strategies and business model under ICH enviroment Dr. Emil Fu, SVP of International Integration, Fountain Medical Development



Session 2: Case Studies of the Latest Innovative Drug Discovery & Development Chair: Dr. Changyu Wang, Founder of Huamian Biotechnology	
13:50-14:15	Antibody Drug Discovery: Challenges and Opportunities Prof. Zhiqiang An, Professor of UT's Institute of Molecular Medicine in Houston
14:15-14:40	Discovery of Xeljanz® (tofacitinib): A First-In-Class JAK Inhibitor for the Treatment of Rheumatoid Arthritis Dr. Mark E Flanagan, Associate Research Fellow, Design and Synthesis Sciences, Pfizer
14:40-15:05	Differentiation Creates Excellence: Hengrui Experience Dr. Lianshan Zhang, Senior Vice President and Global R&D President of Jiangsu Hengrui Medicine Co., Ltd.
15:05-15:30	CART cell therapeutics against solid tumor Dr. Zonghai Li, Chief Executive Officer, Carsgen
15:30-15:55	Construct and application of virion-displayed GPCRs for studying drug-GPCR interactions Prof. Heng Zhu, Department of Pharmacology & Mol Sciences, Johns Hopkins School of Medicine
15:55-16:05	Tea Break & Exhibition & Poster Presentation
Panel Discussion: Cross-border Collaboration and Licensing in New Drug Discovery & Development Chair: Dr. Yuan-Hua Ding, Executive Director and Head of External Science & Innovation (ES&I), Asia-Pacific, Pfizer	
16:05-16:50	Dr. Yuan-Hua Ding, Executive Director and Head of External Science & Innovation (ES&I), Asia-Pacific, Pfizer Dr. Hong Xin, Sr. Director New Ventures, Korea, Johnson & Johnson Innovation, Asia Pacific Innovation Center Dr. Min Wu, Executive Director, Asia Pacific Innovation AP Innovation Hub, BD&L. MSD R&D (China) Co., Ltd. Dr. Bernd Nosse, Global Head BD&L Technologies, Boehringer Ingelheim Pharma GmbH & Co. KG Dr. Biao Zheng, CSO, GenFleet Therapeutics Dr. Yuanwei Chen, CEO, Hinoval Pharmaceuticals
Flash Talk Chair: Dr. Jun Zhou, Vice President of Hangzhou Firestone Technology Co. Ltd.	
16:50-17:02	Discovery of EED Inhibitor BR554: Preclinical Candidate as Anti-Cancer Therapy Dr. Bin Zou, CEO of Shanghai Blueray Biopharma
17:02-17:14	Polymorph Study in Early Drug Development Dr. Stem Hung, Vice President of Solipharma LLC
17:14-17:26	Companion Diagnostics - A Key Element in Precision Medicine Vafa Amirikia, Director, Corporate Strategy and Business Development, Shuwen Biotech Co. Ltd
17:26-17:38	Clinical Quality by Design -- Reinforcing the Process control for early phase clinical trial Dr. Yin Li, Chief Business Officer & Chief Information Officer of Proswell Medical
17:38-17:50	Biotech drug discovery based on the antibody and CAR-T libraries Dr. Jianghai Liu, General Manager of ABlink Biotech Co.,Ltd.
18:00-20:00	Dinner- Junior Ballroom



October 19, 2018 (Grand Ballroom)	
Session 2: Case Studies of the Latest Innovative Drug Discovery & Development Chair: Dr. Lee Babiss, President of SYNBLic Therapeutics	
09:00-09:25	High-Throughput Experimentation for the Optimized Synthesis of TROX-1, a Cav2.2 Blocker for the Treatment of Chronic Pain Dr. Joseph Duffy, Head of External Discovery Chemistry, Merck Research Lab, Merck & Co., Inc.
09:25-09:50	Drugging the Undruggable: Targeting Protein Tyrosine Phosphatases for Novel Therapeutics Prof. Zhong-Yin Zhang, Director, Purdue Institute for Drug Discovery
09:50-10:15	Applications of protein microarrays in basic and clinical research Prof. Jiang Qian, Ophthalmology Department, Johns Hopkins University
10:15-10:40	Nonclinical Safety Assessment of Innovative New Drugs Dr. Xiantang Li, Senior Director, DSRD Asia Lead Drug Safety Research & Development (DSRD), Pfizer Inc
10:40-10:50	Tea Break & Exhibition & Poster Presentation
10:50-11:15	From Bench to Bedside: Discovery of Aimovig™(erenumab-aooe), the First FDA-Approved Antibody Therapeutic for Migraine Dr. Cen Xu, Scientific director, Amgen R&D & Chief Scientific Adviser, Precision BioCapital Inc
11:15-11:40	Innovative applications of 3D tissue engineering technology Dr. Ha Nam Nguyen, Co-founder & CEO of 3Dnamics
11:40-12:05	The Evolving Saga of Research & Development Dr. Lee Babiss, President of SYNBLic Therapeutics
12:05-13:00	Lunch & Exhibition & Poster Presentation
Session 3: New Approaches to Drug Discovery & Development: AI Application, Big Data, Block Chain, etc. Chair: Dr. Lipeng Lai, Co-founder and General Manager of XtalPi-Data and AI Research Center	
13:00-13:25	Drug Discovery Enabled Dr. Petr Vachal, Associate Vice President, Discovery Chemistry, Merck & Co., Inc.
13:25-13:50	Applications of AI in Drug R&D: Practices and Challenges Dr. Lipeng Lai, Co-founder and General Manager of XtalPi-Data and AI Research Center
13:50-14:15	Prediction of Druggable Proteins Using a Word2vec Algorithm Prof. Jianfeng Pei, Associate Professor, Peking University
14:15-14:40	Learning the Art of Chemical Synthesis with Deep Neural Networks and Discipline Scale Data Prof. Mark P. Waller, Physics Department, College of Science, Shanghai University
14:40-15:05	Current situation and trend of new drug R&D in the world via Data perspective Mr. Tianquan Li, Senior engineer, co-founder of Yaozh.com, president of data division of Yaozh.com
15:05-15:15	Tea Break & Exhibition & Poster Presentation
Panel Discussion: Biomedical Investment Environment and Trends Chair: Ms. Lily Zhang, Partner, CDH Investment	
15:15-16:00	Dr. Jin Li, Founder and Chairman & CEO of HitGen Ms. Lily Zhang, Partner, CDH Investment Dr. Yun Zhang, Managing Director, Wushi Venture Mr. Michael Flaschen, Head of China Strategy and Business Development, Aduro Biotechnology Dr. Yi Lin, Managing Partner, Yuansheng BioVenture



Flash Talk	
Chair: Dr. Bin Zou, CEO of Shanghai Blueray Biopharma	
16:00-16:12	Targeting Phosphatases for Drug Development with Innovative Approaches Dr. Wei Chen, CEO of NetVation DL Medicine
16:12-16:24	First-In-Class MyD88 Inhibitors as Early Drug Development Candidates for IRI and other Inflammatory Diseases Dr. Zuyu Guo, CEO & CSO of Wuhan INNA Pharma
16:24-16:36	2018 Clinical Development Success Rates and Licensing Deals Trends Mr. Scott Yu, Director Greater China of Informa
16:36-16:48	Biodiversity as Source for Potential Therapeutic Anti-HBV Drugs Prof. Min Xu, Professor of Kunming University of Technology and Science
16:48-17:00	Improving the efficiency of innovation and cooperation among biomedicine enterprises by industrial digitalization Dr. Jun Zhou, Vice President of Hangzhou Firestone Technology Co. Ltd.
17:00-17:12	Technology Transfer of Natural Active Peptide Bank Mr. Yunpeng Wang, Director of Kunming Angming Technology Co.,Ltd.
17:12-17:30	Closing Remarks Dr. Xianping Lu, Chairman & CEO, Shenzhen Chipscreen Biosciences Co. LTD

8TH INTERNATIONAL SYMPOSIUM ON DNA-ENCODED CHEMICAL LIBRARIES

October 19, 2018 (Junior Ballroom)	
TIME	TOPIC & SPEAKER
08:00-09:00	On-site Registration (5 th Floor)
09:00-09:10	Introduction and Welcome MODERATOR: Dr. Jin Li, Founder and Chairman & CEO of HitGen
Session 1: Development of On-DNA Chemical Synthesis	
Chair: Dr. Barry Morgan, Chief Scientific Officer of HitGen	
09:10-09:40	Employing Photoredox Catalysis for DNA-Encoded Chemistry: Decarboxylative Alkylation of α-Amino Acids Dr. Dominik K. Köelmel, Senior Scientist, Worldwide Research and Development, Pfizer
09:40-10:10	Forging Csp3-Csp3 and Csp3-Csp2 Bonds in DEL-Format Dr. Jie Wang, Post doctor, Department of Chemistry, The Scripps Research Institute



10:10-10:40	Encoded Self-Assembling Chemical (ESAC) Libraries Prof. Dario Neri, Professor, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology
10:40-11:00	Tea Break + Poster Presentation
11:00-11:30	Enzyme substrate and covalent crosslinking DEL selection assays for enrichment of low affinity ligands and for targeting proteins within live cells Prof. Casey J. Krusemark, Assistant Professor, Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University
Session 2: New Technologies for DNA-encoded Library Selection and Hit Identification Chair: Prof. Dario Neri, Professor, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich) & Co-founder of Philogen	
11:30-12:00	Optimizing Hit Discovery from a 200 Billion Compound DEL Library Collection Dr. David Israel, Vice President of Lead Discovery Sciences, HitGen
12:00-13:00	Lunch + Poster Presentation
13:00-13:30	The Encoded Library Technology Data Analysis Platform at GSK Dr. Kenneth E Lind, Manager – Scientific Computing, R&D Platform Technology & Science, GSK
13:30-14:00	DNA-Programmed Chemistry: Application to Lead Expansion of a Peptide Macrocycle Dr. John R Jacobsen, Senior Vice President, Chemistry, DiCE Molecules SV, Inc
Session 3: Case Studies: Clinical Candidates from DNA-Encoded Libraries Chair: Dr. Nick Terrett, VP of European Chemistry Lead, Merck Sharp & Dohme Research GmbH	
14:00-14:30	Identification of Highly Potent and Selective Receptor Interacting Protein 1(RIP1) Kinase Inhibitors via DNA-Encoded Libraries Technology (ELT) Dr. Yue Li, Investigator, Medicinal Chemistry, NCE Molecular Discovery, GlaxoSmithKline
14:30-14:50	Tea Break + Poster Presentation
14:50-15:20	Use of DNA encoded libraries at Roche Dr. Alexander L. Satz, Senior Principal Scientist, Roche
15:20-15:50	Characterization of specific Naa50 inhibitors identified using a DNA encoded library: a lead-finding case study for a challenging target Dr. Pei-Pei Kung, Associate research fellow of Pfizer
15:50-16:20	Therapeutic Discovery and Technology Development with the X-Chem DNA-Encoded Chemistry Platform Dr. Anthony Keefe, Vice President of Discovery Technology, X-Chem Pharmaceuticals



Panel Discussion

Chair: Dr. Robert Goodnow, VP, Innovation Chemistry, Pharmaron

16:20-17:20	<p>Dr. Barry Morgan, Chief Scientific Officer, HitGen</p> <p>Prof. Dario Neri, Professor, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich) & Co-founder of Philogen</p> <p>Prof. Casey Krusemark, Assistant Professor, Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University</p> <p>Dr. Jin Li, Founder, Chairman & CEO, HitGen</p> <p>Dr. Alexander Satz Lee, Senior Principal Scientist, Roche</p> <p>Dr. Anthony D Keefe, Vice President, Discovery Technology, X-Chem Pharmaceuticals</p> <p>Dr. Nick Terrett, Scientific Associate Vice President of European Chemistry Lead, Merck Sharp & Dohme Research GmbH</p> <p>Dr. Kenneth E Lind, PhD, Manager-Scientific Computing, R&D Platform Technology & Science, GSK</p> <p>Prof. Xiaojie Lu, Principal Investigator, Shanghai Institute of Materia Medica</p> <p>Prof. Xiaoyu Li, Associate Professor, University of Hongkong</p>
17:20-17:30	<p>Closing Remarks</p> <p>Prof. Dario Neri, Professor, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich) & Co-founder of Philogen</p>